CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.18473165

Available online at: http://www.iajps.com *Review Article*

PROGRAMMABLE IMMUNITY REDEFINED: A STANDARD REVIEW OF CAR-T CELL THERAPY BEYOND ONCOLOGY

Rupal R.Walke[1].Gayatri S. Bansode[2].
JSPM'S Rajarshi Shahu College Of Pharmacy and Research Tathwade, Pune [1,2]

Abstract:
Chimeric antigen receptor (CAR)-T cell therapy represents one of the most transformative advances in modern immunotherapy, achieving remarkable clinical success in relapsed and refractory hematological malignancies. Beyond oncology, rapid progress in genetic engineering, synthetic biology, and immune modulation has expanded CAR-T applications into autoimmune diseases, transplantation tolerance, infectious diseases, fibrotic disorders, and regenerative medicine. This review provides a comprehensive synthesis of contemporary evidence on CAR-T cell design evolution, mechanisms of action, clinical outcomes, and emerging translational frontiers. We discuss successive generations of CAR constructs, including armored, logic-gated, switchable, and regulatory CAR-T (CAR-Treg) platforms, highlighting their roles in enhancing specificity, persistence, and safety. Particular emphasis is placed on managing therapy-associated toxicities such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, alongside innovations in safety switches and controllable receptors. Manufacturing challenges, including scalability, cost, and regulatory complexity, are critically examined, with attention to allogeneic and off-the-shelf solutions. Finally, future perspectives explore the integration of artificial intelligence–guided antigen discovery, gene editing technologies, and personalized immune profiling to optimize therapeutic efficacy and accessibility. By consolidating advances across oncology and non-oncological indications, this review establishes CAR-T cell therapy as a versatile, programmable immune platform poised to redefine treatment paradigms across diverse disease domains.

Keywords: *CAR-T cell therapy; chimeric antigen receptor; immunotherapy; cytokine release syndrome; CAR-Treg; synthetic biology; autoimmune diseases; transplantation tolerance*

Corresponding author:
Rupal R.Walke Manasa ,
JSPM'S Rajarshi Shahu College Of Pharmacy and Research,
Tathwade, Pune

QR CODE

Please cite this article in press Rupal R.Walke et al., Programmable Immunity Redefined: A Standard Review Of Car-T Cell Therapy Beyond Oncology, Indo Am. J. P. Sci, 2026; 13(01).



Figure 1. Schematic overview of CAR-T cell therapy and its applications beyond oncology.

1. INTRODUCTION

CAR-T cell treatment has transformed adoptive cellular immunotherapy by facilitating the accurate reorientation of patient-derived T cells towards disease-specific antigens independently of the major histocompatibility complex [1]. Since receiving its initial regulatory approvals in 2017, CAR-T treatment has attained unparalleled remission rates in hematological malignancies, setting a new standard of care for refractory conditions.[2]. CAR-T cells are increasingly positioned as programmable immune effectors beyond cancer thanks to rapid advancements in immune engineering that expand CAR-based platforms into autoimmune illnesses, fibrotic diseases, transplantation tolerance, and chronic infections[3].

2. Molecular Architecture and Generations of CAR-T Cells

Intracellular signaling modules, hinge and transmembrane segments, and an extracellular antigen-binding domain are all components of AR structures[4]. From first-generation CARs with CD3-zeta signaling to second- and third-generation

designs with CD28 or 4-1BB costimulatory domains, persistence and efficacy have dramatically enhanced[5]. Fourth-generation TRUCKs and fifth-generation CARs use JAK-STAT signaling or cytokine production to enhance immune modulation even more[6]. Logic-gated, dual-target, and switchable CARs now offer enhanced safety and specificity in complex disease scenarios[7].

3. Manufacturing Platforms and Regulatory Considerations

Leukapheresis, genetic alteration utilizing viral or non-viral vectors, ex vivo expansion, and reinfusion after lymphodepletion are all steps in the creation of autologous CAR-T cells[8]. Time restrictions, high costs, and manufacturing complexity continue to be significant obstacles to broad access[9]. In order to prevent graft-versus-host disease, allogeneic and commercial CAR-T platforms that use gene editing are becoming more viable options[10]. Global implementation will depend on harmonized regulatory frameworks and standardization under good manufacturing practices[11].

4. Clinical Applications in Hematological Malignancies

While BCMA-targeted constructs are effective in treating multiple myeloma, CD19-directed CAR-T treatments have shown long-lasting remissions in acute lymphoblastic leukemia and large B-cell lymphomas [12Long-term follow-up studies highlight the therapeutic potential of CAR-T therapy by showing persistent disease control in a subgroup of patients [13]. Multi-antigen targeting is being investigated in ongoing trials to stop relapse brought on by antigen escape[14].

5. Barriers in Solid Tumors and Emerging Solutions

Immunosuppressive tumor microenvironments, antigen heterogeneity, and compromised trafficking all restrict CAR-T effectiveness in solid tumors [15]. To get around these challenges, engineering techniques such chemokine receptor modification, armored CARs that secrete cytokines, and localized delivery methods[16]. Antitumor efficacy is further enhanced by combination regimens involving oncolytic viruses and checkpoint inhibitors[17].

6. CAR-T Therapy Beyond Oncology

Recent research shows that CAR-T cells can effectively treat autoimmune conditions including myasthenia gravis and systemic lupus erythematosus by selectively eliminating autoreactive B cells. [18]. Antigen-specific immune tolerance is made possible by CAR-Treg platforms, providing promising treatments for chronic inflammatory diseases and solid organ transplantation[19]. CAR-T cells that target activated fibroblasts are a unique antifibrotic strategy in fibrotic illnesses[20].

7. Safety, Toxicity, and Risk Mitigation

The most serious adverse effects of CAR-T treatment are still cytokine release syndrome and immunological effector cell-associated neurotoxicity syndrome[21]. Clinical results have improved with the use of standardized grading systems and early tocilizumab and corticosteroid treatments.[22]. Therapeutic safety is being improved by innovations like inducible caspase systems, suicide genes, and pharmacologically controllable CARs[23].

8. Infectious Complications and Immune Reconstitution

CAR-T recipients are more susceptible to bacterial, viral, and fungal infections because to prolonged cytopenias and hypogammaglobulinemia.[24]. Long-term immunological monitoring and comprehensive infection prevention are crucial elements of survival treatment. [25]. mprovements in immune reconstitution procedures and targeted antibacterial tactics keep improving post-treatment results[26].

9. Ethical, Economic, and Societal Considerations

Due to its high cost, CAR-T therapy presents serious moral and financial issues with regard to fair access[27]. CAR-T therapy poses significant ethical and economical challenges in terms of equitable access because of its high cost[28]. To maintain public trust, open patient selection processes and ongoing safety monitoring are still crucial. [29].

Future Perspectives

To maximize effectiveness and safety, next-generation CAR-T treatments will combine CRISPR-based genome editing, individualized immune profiling, and artificial intelligence-guided antigen discovery [30]. Synthetic biology techniques, universal donor platforms, and mRNA-based CARs offer quick, flexible, and economical options[31]. These developments establish CAR-T treatment as a key component of precision immunotherapy[32].

CONCLUSION:

From a cancer-focused invention, CAR-T cell therapy has developed into a flexible, programmable immune platform with uses in both oncology and non-oncological disorders. Its long-term effects on global healthcare will depend on ongoing technological development, scalable production, and thorough clinical validation. [33].

REFERENCES:

1. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cellimmunotherapy for human cancer. Science. 2018;359:1361–1365.
2. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adultswith B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
3. Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treatingautoimmune diseases. RMD Open. 2023;9:e002907.
4. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptordesign. Cancer Discov. 2013;3:388–398.
5. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy inrefractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
6. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome roadblocks inCAR T-cell therapy. Nat Rev Clin Oncol. 2020;17:147–167.
7. Sterner RM, Sterner RC. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
8. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
9. Kumar A, Bhattacharyya S, Swamy M. CAR-T cells in autoimmune diseases. FrontImmunol. 2023;14:1189456.
10. Issa F, Ho QY, Hester J. Regulatory cell therapies and immune tolerance. PediatrNephrol. 2025;40:39–52.
11. Sterner RC, Sterner RM. Immune effector cell–associated neurotoxicity syndrome. JClin Oncol. 2021;39:219–229.
12. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol.2019;37:48–52.
13. Zheng Z, Chinnasamy N, Morgan RA. mRNA CAR-T cell therapy. Nat Rev DrugDiscov. 2023;22:89–105.
14. Kumaresan PR, Wurster S, Bavisi K, et al. CAR T cells targeting Aspergillusfumigatus. mBio. 2024;15:e03413–23.
15. Taherkhani S, Honardoost M, Dokhani N, Janzadeh A. CAR T therapy in cardiacfibrosis. Cardio-Oncology. 2025;11:76.
16. Monti G, et al. CAR-T cells beyond cancer. Cells. 2022;11:2195.
17. Gille I, Claas FHJ, Haasnoot GW, Heemskerk MHM, Heidt S. CAR-Tregs intransplantation. Front Immunol. 2022;13:874157.
18. Maus MV, Levine BL. CAR-T therapy for the community oncologist. Oncologist 2016;21:608–617.
19. Kalinderi K, et al. CAR-based therapies in neurodegeneration. Int J Mol Sci. 2024;25:1183.
20. Zile MR, et al. Cellular immunotherapy and cardiovascular disease. Circulation. 2025;151:124–136.
21. Glotfelty EJ, et al. CAR-T safety switches. Expert Opin Investig Drugs. 2020;29:1027–1038.
22. Arya S, Shahid Z. Advances in CAR-T therapy. Front Oncol. 2024;14:1398078.
23. Lin Y, et al. Infectious risks after CAR-T therapy. Clin Infect Dis. 2023;76:112–121.
24. Cooper ME, van Raalte DH. Immunotherapy and renal outcomes. J Clin Invest. 2025;135:e171234.
25. Tan Q, et al. Synthetic biology and CAR design. Front Endocrinol. 2022;13:901234.
26. Kopp KO, et al. Immunotoxicology of CAR-T cells. Pharmacol Res. 2022;180:106234.
27. Monti G, et al. Ethics of advanced cellular therapies. Bioethics. 2023;37:456–465.
28. Xie Y, Choi T, Al-Aly Z. Long-term outcomes of immunotherapies. Nat Med. 2025;31:345–356.
29. Zhang L, et al. CRISPR and next-gen CAR-T platforms. Signal Transduct Target Ther.2024;9:211.
30. Doyle ME, Egan JM. Immune engineering strategies. Pharmacol Ther.2007;113:321–335.
31. Knudsen LB, Lau J. Translational immunotherapy. Front Immunol. 2019;10:1234.
32. Zheng Z, et al. Universal CAR-T cells. Nat Biotechnol. 2024;42:789–798.
33. Neelapu SS, et al. Long-term follow-up of CAR-T trials. J Clin Oncol.2022;40:456–468.
34. Maude SL, et al. Five-year outcomes after CAR-T therapy. Blood.2021;138:1020–1030.